Retreatment of hepatitis C — sofosbuvir/velpatasvir/ voxilaprevir (SOF/VEL/VOX) 2

All consecutive patients receiving SOF/VEL/VOX in 27 centers
in northern Italy from May – October 2018 were enrolled in a
real life study.

EACS Guidelines

Magazine